Results 231 to 240 of about 118,583,499 (297)
Bone mineral density, bone remodeling biomarkers, and hemostatic correlates in hemophilia and von Willebrand disease. [PDF]
Blood AdvCitla-Sridhar D +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Emergency Medicine Clinics of North America, 1993
Hemophilia and von Willebrand's disease are the most common hereditary bleeding disorders. A variety of treatment modalities of these disorders are discussed. Common organ system bleeding and its treatment and disposition are outlined. Finally, potential complications of both the disease and treatment are reviewed.
J A, Pfaff, M, Geninatti
openaire +2 more sources
Hemophilia and von Willebrand's disease are the most common hereditary bleeding disorders. A variety of treatment modalities of these disorders are discussed. Common organ system bleeding and its treatment and disposition are outlined. Finally, potential complications of both the disease and treatment are reviewed.
J A, Pfaff, M, Geninatti
openaire +2 more sources
Pediatrics In Review, 1991
Hemophilia is a hereditary bleeding disorder characterized by Factor VIII (F-VIII) or Factor IX (F-IX) deficiency, bleeding into joints and soft tissues, and an X-linked mode of inheritance. Approximately one third of new cases occur as spontaneous mutations, with no family history of hemophilia.
J M, Lusher, I, Warrier
openaire +2 more sources
Hemophilia is a hereditary bleeding disorder characterized by Factor VIII (F-VIII) or Factor IX (F-IX) deficiency, bleeding into joints and soft tissues, and an X-linked mode of inheritance. Approximately one third of new cases occur as spontaneous mutations, with no family history of hemophilia.
J M, Lusher, I, Warrier
openaire +2 more sources
A Challenge for Hemophilia Treatment: Hemophilia and Cancer
Journal of Pediatric Hematology/Oncology, 2020Background: The risk of developing cancer increases with age and also adverse environmental conditions. The same holds true in the aging people with hemophilia (PwH). Furthermore, cancer is an important challenge for physicians working in multidisciplinary hemophilia care centers. Aim:
Basak, Koc, Bulent, Zulfikar
openaire +2 more sources
Hematology/Oncology Clinics of North America, 1992
Over the past few years considerable progress has been made in elucidating the molecular genetics of hemophilia A, in carrier detection and prenatal diagnosis, and in the production of safer clotting factor concentrates. Recombinant FVIII, shown to be safe and effective in ongoing prelicensure clinical trials that began in the spring of 1987, should ...
J M, Lusher, I, Warrier
openaire +2 more sources
Over the past few years considerable progress has been made in elucidating the molecular genetics of hemophilia A, in carrier detection and prenatal diagnosis, and in the production of safer clotting factor concentrates. Recombinant FVIII, shown to be safe and effective in ongoing prelicensure clinical trials that began in the spring of 1987, should ...
J M, Lusher, I, Warrier
openaire +2 more sources
Pediatric Clinics of North America, 1980
The clinical manifestations of hemophilia depend upon both age and the severity of the factor VIII or IX deficiency. Hemophilia A and B cannot be differentiated on clinical grounds. Laboratory tests include platelet count, prothrombin time, partial thromboplastin time, and bleeding time.
openaire +2 more sources
The clinical manifestations of hemophilia depend upon both age and the severity of the factor VIII or IX deficiency. Hemophilia A and B cannot be differentiated on clinical grounds. Laboratory tests include platelet count, prothrombin time, partial thromboplastin time, and bleeding time.
openaire +2 more sources
Blood Coagulation in Hemophilia A and Hemophilia C
Blood, 1998Tissue factor (TF)-induced coagulation was compared in contact pathway suppressed human blood from normal, factor VIII-deficient, and factor XI-deficient donors. The progress of the reaction was analyzed in quenched samples by immunoassay and immunoblotting for fibrinopeptide A (FPA), thrombin-antithrombin (TAT), factor V activation, and osteonectin ...
Cawthern, K. M. +5 more
openaire +3 more sources
Pseudotumor of hemophilia in the mandible of a patient with hemophilia A
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2012Hemophilic pseudotumor is a rare lesion that is essentially a progressive, slowly expanding, encapsulated hematoma. It is estimated to affect 1% to 2% of severe hemophiliacs. The majority of hemophilic pseudotumors occur within soft tissues (intramuscular) and long bones of adult males. Fewer than 20 cases have been reported in the maxillofacial region.
Roger R, Throndson +3 more
openaire +2 more sources